APA

Buckheit R. W., Hollingshead M., Stinson S., Fliakas-Boltz V., Pallansch L. A., Roberson J., Decker W., Elder C., Borgel S., Bonomi C., Shores R., Siford T., Malspeis L. & Bader J. P. (19970620). Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. : AIDS research and human retroviruses.

Chicago

Buckheit R W, Hollingshead M, Stinson S, Fliakas-Boltz V, Pallansch L A, Roberson J, Decker W, Elder C, Borgel S, Bonomi C, Shores R, Siford T, Malspeis L and Bader J P. 19970620. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. : AIDS research and human retroviruses.

Harvard

Buckheit R. W., Hollingshead M., Stinson S., Fliakas-Boltz V., Pallansch L. A., Roberson J., Decker W., Elder C., Borgel S., Bonomi C., Shores R., Siford T., Malspeis L. and Bader J. P. (19970620). Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. : AIDS research and human retroviruses.

MLA

Buckheit R W, Hollingshead M, Stinson S, Fliakas-Boltz V, Pallansch L A, Roberson J, Decker W, Elder C, Borgel S, Bonomi C, Shores R, Siford T, Malspeis L and Bader J P. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1. : AIDS research and human retroviruses. 19970620.